An Immunological Toolkit for Clinical Application
Lead Research Organisation:
Newcastle University
Department Name: Institute of Cellular Medicine
Abstract
Patients with rheumatoid arthritis (RA) suffer with joint pain and stiffness, and joint damage which leads to a reduced ability to carry out everyday tasks. Although these are the most obvious features of the disease, the root cause of the disease lies within the human immune system. At the moment we don?t fully understand the immune abnormalities that lead to RA but, if we did, this should help us to manage the disease better. It would become easier to make a diagnosis, as well as to determine whether a patient?s RA is likely to damage their joints in the future. Perhaps most importantly it would help us to design better drugs to combat the disease, and to better use the drugs that already exist. Something that we would really like to be able to do is to decide the most appropriate drug for each patient and a better understanding of the immune abnormalities would also help here.
Therefore our plans are to study, in detail, the immune system of patients with RA. This will involve taking blood from patients and running a panel of advanced laboratory tests on their white blood cells. We will compare the results we obtain with the immune changes in healthy individuals responding to a vaccine ? expecting some to be the same and some to be different. Our work is in three phases and, during the phases, we plan to slowly ?home in? on simple laboratory tests that will allow us to measure what is happening to the immune system in patients with RA. An exciting aspect of the work is that what is relevant to RA may also relate to other diseases (diabetes, multiple sclerosis, asthma) and to patients with an organ transplant. Therefore our results could have wide-ranging influence beyond improving the care of patients with RA
Therefore our plans are to study, in detail, the immune system of patients with RA. This will involve taking blood from patients and running a panel of advanced laboratory tests on their white blood cells. We will compare the results we obtain with the immune changes in healthy individuals responding to a vaccine ? expecting some to be the same and some to be different. Our work is in three phases and, during the phases, we plan to slowly ?home in? on simple laboratory tests that will allow us to measure what is happening to the immune system in patients with RA. An exciting aspect of the work is that what is relevant to RA may also relate to other diseases (diabetes, multiple sclerosis, asthma) and to patients with an organ transplant. Therefore our results could have wide-ranging influence beyond improving the care of patients with RA
Technical Summary
Current management of rheumatoid arthritis (RA) is based upon measurement of inflammation and tissue damage. However these are downstream consequences of immune dysregulation, and sub-optimal guides for managing patients and designing disease-modifying drugs. Our aim is to identify the key immune abnormalities that define RA and to develop an immunological toolkit: a set of functional and flow cytometry-based assays to study and monitor the dysfunctional immune system. A UK-wide collaboration of academic and industrial scientists will develop the toolkit, using regular discussions and workshops. Although current theory suggests that key immune abnormalities in RA should reside within T- or B- lymphocytes, lessons from other diseases suggest a discovery approach to be most appropriate, encompassing deep immunophenotyping of major peripheral blood immune and inflammatory cell subsets. Therefore in phase I purified CD4+ and CD8+ T-cells, B-cells, monocytes, NK cells and neutrophils will undergo: multiparameter flow cytometry for cell surface phenotype, intracellular cytokine and lineage transcription factor expression, and signalling pathways; transcriptional analysis using Affymetrix U219 microarrays; and small RNA sequencing. A well-defined subset (n=30) will subsequently undergo ultra-deep RNA sequencing, providing a complete picture of the RA transcriptome. We will study three sets of individuals: 30 healthy controls during an evolving vaccination response; 200 established RA patients, stratified for disease activity and disease duration; and 30 RA patients receiving abatacept (costimulation blockade). Hypothesis-generating phase I will provide a detailed signature of cells and pathways that characterise the RA immune system, and inform the design of customised, low-density array(s) (LDA), alongside the initial development of relevant in vitro immune function assays. In phase II these will be applied to 100 patients with recent onset inflammatory arthritis, sampled longitudinally, alongside a refined panel of flow cytometry protocols. Signals that are consistent between phases I and II will lead to further refinement of the in vitro assays ready for phase III, which encompasses proof-of-concept studies with novel therapeutic compounds, provided by industrial partners. Here the final immune toolkit will be ?road tested?, providing a secondary outcome measure that predicts conventional efficacy parameters. Success in this challenging programme will provide a novel portfolio of immune function assays, potentially applicable to RA but also other immunopathologies. Their widespread adoption and application across diseases will reinforce the successful image of UK translational immunological research. Intellectual property generated by the work will be protected for future exploitation as appropriate.
Organisations
- Newcastle University, United Kingdom (Collaboration, Lead Research Organisation)
- University of Edinburgh, United Kingdom (Collaboration)
- Amgen Inc (Collaboration)
- Manchester University (Collaboration)
- Oslo University Hospital (Collaboration)
- Hospital de Madrid (Collaboration)
- University of Amsterdam (Collaboration)
- Chiltern International (Collaboration)
- AstraZeneca plc (Collaboration)
- Leibniz Association (Collaboration)
- Leiden University Medical Center (Collaboration)
- University of Oxford, United Kingdom (Collaboration)
- Reade (Collaboration)
- UCB Pharma, Belgium (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- University of Glasgow, United Kingdom (Collaboration)
- University of Birmingham, United Kingdom (Collaboration)
- Pfizer Ltd (Collaboration)
- Royal Berkshire Hospital (Collaboration)
- Pfizer, United States (Collaboration)
- MedImmune (Collaboration)
- University Hospital of Erlangen (Collaboration)
- Tepnel Pharma Services (Collaboration)
- Versus Arthritis (Collaboration)
- St. George Hospital (Collaboration)
- Addenbrooke's Hospital (Collaboration)
- King's College London, United Kingdom (Collaboration)
- University College London, United Kingdom (Collaboration)
- University of Bath, Bath (Collaboration)
- Protagen AG (Collaboration)
- NIHR CRN staff and facilities throughout the UK (Collaboration)
- SomaLogic (Collaboration)
- Queen Mary, University of London, United Kingdom (Collaboration)
- Cardiff University, United Kingdom (Collaboration)
- Abbott (Collaboration)
- Johnson & Johnson Ltd, United Kingdom (Collaboration)
- University of Queensland, Australia (Collaboration)
- University of Sheffield, United Kingdom (Collaboration)
- F. Hoffmann-La Roche AG (Collaboration)
- Sanofi (Collaboration)
- Apitope (Collaboration)
- University of Warwick, United Kingdom (Collaboration)
- University of Hertfordshire, United Kingdom (Collaboration)
- Karolinska Institute, Sweden (Collaboration)
- Sanquin (Collaboration)
- Viapath (Collaboration)
- University of Cambridge, United Kingdom (Collaboration)
- Regional University Hospital of Tours (Collaboration)
- University of Leeds, United Kingdom (Collaboration)
- Simomics Ltd (Collaboration)
- Bristol-Myers Squibb (Collaboration)
- European Translational Information and Knowledge Management Services (eTRIKS) (Collaboration)
- NHS London, United Kingdom (Collaboration)
- University of Manchester, Manchester, United Kingdom (Collaboration)
Publications
Anderson AE
(2019)
Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis.
in Rheumatology (Oxford, England)
Anderson AE
(2016)
IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis.
in Annals of the rheumatic diseases
Bluett J
(2014)
Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.
in The pharmacogenomics journal
Brown PM
(2016)
Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.
in Nature reviews. Rheumatology
Carmona FD
(2017)
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
in American journal of human genetics
Cooles FA
(2016)
Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies.
in Arthritis research & therapy
Cooles FAH
(2018)
The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy.
in The Journal of allergy and clinical immunology
Cooles FAH
(2018)
Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid Arthritis.
in Frontiers in immunology
| Description | A: Arthritis Research UK Disease Subcommittee Meeting, Chesterfield, 2018 |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| URL | https://www.versusarthritis.org/research/research-funding-and-policy/our-charitable-subcommittees/ |
| Description | A: CLUSTER Consortium, London 2018 - Stratified Medicine in JIA and associated Uveitis |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| URL | https://www.arthritisresearchuk.org/research/grant-tracker-items/2018/personalised-treatment-for-chi... |
| Description | A: NIHR ARUK Musculoskeletal Experimental Medicine Conference 2018, Nottingham 2018 |
| Geographic Reach | National |
| Policy Influence Type | Participation in a national consultation |
| URL | https://www.arthritisresearchuk.org/research/news-for-researchers/2018/july/maximising-msk-experimen... |
| Description | Arthritis Research UK Strategic Workshop - Stacking the Odds Towards a Cure - Versus Arthritis London 2018 |
| Geographic Reach | National |
| Policy Influence Type | Participation in a national consultation |
| Description | BBA Forum Meeting London 2016 British Biosimilar Association Clinical Faculty |
| Geographic Reach | National |
| Policy Influence Type | Participation in a national consultation |
| Description | Chair - EULAR STUDY GROUP ON THERAPEUTIC DRUG MONITORING OF BIOLOGICS |
| Geographic Reach | Europe |
| Policy Influence Type | Membership of a guideline committee |
| URL | https://www.eular.org/myUploadData/files/publication_document_therapeutic_drug_monitoring_study_grou... |
| Description | Department of Health and Social Care Visit to NIHR Newcastle Biomedical Research Centre - Tony Soteriou |
| Geographic Reach | National |
| Policy Influence Type | Participation in a national consultation |
| Description | MHRA CTBVAG |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Description | MHRA GRID advisory group |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Description | MRC Informatics Meeting London 2016 |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | MRC Stratified Medicine Leads met to discuss big data and data sharing in medical research. |
| Description | MRC Methodology for Stratified Medicine |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Description | MRC Population and Systems Medicine Board |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Description | MRC Translational Research Group London 2018 |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| URL | https://mrc.ukri.org/about/our-structure/strategy-board-overview-groups/translational-research-group... |
| Description | MRC Translational Research Group, London, 2019 |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| URL | https://mrc.ukri.org/about/our-structure/strategy-board-overview-groups/translational-research-group... |
| Description | MRC/ABPI Steering Group |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | Model collaborative parterships with industry |
| Geographic Reach | National |
| Policy Influence Type | Citation in other policy documents |
| Description | NICE Assessment Sub-Group Meeting for the Diagnostics Assessment Programme, Manchester 2018 |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| URL | https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-diagnostics-guidance |
| Description | NICE Meeting |
| Geographic Reach | National |
| Policy Influence Type | Participation in a national consultation |
| Description | NIHR BRC Impact Showcase, Newcastle, 2018 |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Influential meeting on Healthy Ageing as a research priority of national importance, as exemplified by our NIHR BRC. |
| URL | https://www.newcastlebrc.nihr.ac.uk/nihr-newcastle-biomedical-research-centre-impact-showcase-presen... |
| Description | NIHR Bioresource Meeting |
| Geographic Reach | National |
| Policy Influence Type | Participation in a national consultation |
| Description | Newcastle Audit Meeting |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Office for Life Life Sciences Visit (Kristen McLeod) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a national consultation |
| Description | Oslo anti-TNF Tendering Meeting 2017 |
| Geographic Reach | Europe |
| Policy Influence Type | Gave evidence to a government review |
| Impact | Tendering meeting to determine anti-TNF tariffs for the next two years. Keynote speaker. |
| Description | RT-CURE Regulatory meeting with MHRA, representing RT-CURE regulatory subgroup |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a national consultation |
| URL | https://www.rtcure.com/ |
| Description | TRC Steering Committee, London, 2018 with VA and NOCRI |
| Geographic Reach | National |
| Policy Influence Type | Participation in a national consultation |
| Description | Tocilizumab clinical guidelines for British Society for Rheumatology |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| URL | http://rheumatology.oxfordjournals.org/content/53/7/1344.long |
| Description | Translational Research Collaboration for Joint & related inflammatory diseases- Steering Committee Meeting |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| URL | http://www.nihr.ac.uk/life-sciences-industry/access-to-expertise-and-collaborations/collaborations-f... |
| Description | Wellcome Trust 4WARD Meeting 2016 - Clinical PhD Funding - Newcastle, Leeds, Manchester, Sheffield |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Consortium Clinical PhD Funding Meeting |
| URL | http://www.4wardnorth.org.uk/ |
| Description | APIPPRA |
| Amount | £66,120 (GBP) |
| Funding ID | BH149466 |
| Organisation | King's College London |
| Department | School of Medicine KCL |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2015 |
| End | 02/2019 |
| Description | Abbvie Investigator initiated funding |
| Amount | £109,465 (GBP) |
| Funding ID | BH137913 |
| Organisation | AbbVie Inc |
| Sector | Private |
| Country | Global |
| Start | 12/2013 |
| End | 09/2015 |
| Description | BIOFLARE - Biological factors that limit sustained remission in Rheumatoid Arthritis |
| Amount | £2,825,228 (GBP) |
| Funding ID | MR/N026977/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2019 |
| Description | BRC Clinical Training Fellowship |
| Amount | £60,000 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2019 |
| Description | Bridging the third translational gap between industry and academia, creating a strong innovation culture at NU industry. |
| Amount | £250,000 (GBP) |
| Funding ID | MC_PC_17198 |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 09/2019 |
| Description | EMINEMT: Investigating Oncostatin M as a Mediator of Seronegative Inflammatory Arthritis |
| Amount | £127,200 (GBP) |
| Funding ID | MR/S50239X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 10/2019 |
| Description | EU IMI2 (Rheuma Tolerance for Cure [RTCure]) - KCL |
| Amount | € 6,000,000 (EUR) |
| Funding ID | 777357 |
| Organisation | European Commission |
| Department | Innovative Medicines Initiative (IMI) |
| Sector | Multiple |
| Country | European Union (EU) |
| Start | 06/2017 |
| End | 05/2022 |
| Description | EU IMI2 (Rheuma Tolerance for Cure [RTCure]) - Newcastle |
| Amount | € 6,000,000 (EUR) |
| Funding ID | 777357 |
| Organisation | European Commission |
| Department | Innovative Medicines Initiative (IMI) |
| Sector | Multiple |
| Country | European Union (EU) |
| Start | 06/2017 |
| End | 05/2022 |
| Description | Immune-mediated inflammatory disease biobanks in the UK - IMIDBio_UK |
| Amount | £218,084 (GBP) |
| Funding ID | MR/R014191/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2020 |
| Description | Investigation into serum interferon-a as a prognostic marker of clinical response in early RA |
| Amount | £15,100 (GBP) |
| Organisation | British Society for Rheumatology (BSR) |
| Sector | Learned Society |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2019 |
| Description | Investigation into serum interferon-a as a prognostic marker of clinical response in early RA |
| Amount | £15,143 (GBP) |
| Organisation | British Society for Rheumatology (BSR) |
| Sector | Learned Society |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 08/2019 |
| Description | Investigation of methotrexate metabolites in CD4+ T-Lymphocytes as a predictor of response to treatment in Rheumatoid Arthritis |
| Amount | £263,289 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2020 |
| Description | MATURA |
| Amount | £550,614 (GBP) |
| Funding ID | BH137922 |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2014 |
| End | 03/2018 |
| Description | MRC DiMeN DTP Studentiship: What fundamental dysregulation of the immune system underpins the development of rheumatoid arthritis? |
| Amount | £76,000 (GBP) |
| Funding ID | 2117973 |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2019 |
| Description | NIHR Newcastle Biomedical Research Centre in Ageing and Long-term conditions |
| Amount | £17,460,811 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2022 |
| Description | NIHR Translational Research Partnership |
| Amount | £159,422 (GBP) |
| Funding ID | BH122579 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2012 |
| End | 09/2018 |
| Description | Proximity to Discovery |
| Amount | £250,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2015 |
| End | 12/2016 |
| Description | The Rheumatoid Arthritis Muscle Study RAMUS: JAK inhibition and rheumatoid cachexia |
| Amount | £255,650 (GBP) |
| Organisation | Pfizer Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 10/2020 |
| Description | Translation and Diagnostics - bridging the third translational gap |
| Amount | £100,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 08/2018 |
| Title | RA-MAP Systems Model |
| Description | Network-based and cross-platform models of response to treatment in rheumatoid arthritis. |
| Type Of Material | Model of mechanisms or symptoms - human |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | Currently in development the model and data to be made available by 2020. |
| URL | https://research.ncl.ac.uk/ra-map/ |
| Title | The RA-MAP Immunological Toolkit |
| Description | This development of this suite of immune biomarkers - the toolkit - is the major objective of the RA-MAP Consortium. It will be developed from biological material derived at 3 monthly intervals from TACERA study participants. |
| Type Of Material | Biological samples |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | In progress. Ongoing collaborations to 1) validate MATURA methotrexate responders and 2) validate Newcastle interferon gene signature. |
| URL | https://research.ncl.ac.uk/ra-map/ |
| Title | Diversity analysis of flow cytometry data |
| Description | A novel method to measure diversity of immune cells in RA patients, which can be used to detect changes in the immune profiling over time and to categorise RA patients into a number of subgroups (eg remission / non-remission at 6 months) |
| Type Of Material | Data analysis technique |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | None yet. |
| Title | FEMERA: Functional Endotyping Model for Early RA |
| Description | Projection of multi-dimensional data onto two dimensions for consistency scoring and identification of TNF-reactive and Lymphocytic RA endotypes. |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | Application of a method developed by SimOmics permitting identification of endotypes in RA and mapping them to a systems model of RA. |
| Title | IMID-BIO UK Database |
| Description | Cross-consortia collaboration bringing together databases across the immune-mediated inflammatory diseases. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2019 |
| Provided To Others? | No |
| Impact | Validation of MATURA methotrexate responder signature. Validation of Newcastle interferon gene signature. |
| URL | https://gtr.ukri.org/projects?ref=MR%2FR014191%2F1 |
| Title | MedSciNet EDC for TACERA study |
| Description | A study specific Electronic Data Capture (EDC) system has been designed for the TACRA study. This will be the electronic Case Record Form (eCRF) for the study as well as forming part of the Study Management system. The system will also automatically enrol patients once they have been deemed eligible. The EDC system is designed to follow the order of the study assessments and include all the clinical data (incl. Medication history, lifestyle factors questionnaire, DAS28 etc). |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | The clinical dataset will be archived after the TACERA study closure and data will be available to other researchers upon request. |
| Title | PRE-RA: Predictors of Remission in Early RA. |
| Description | A cross-platform multi-omics model of predictors of remission for stratification of early RA patients. |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | In preparation. |
| Title | RA-MAP Predictors of Remission |
| Description | We have amalgamated 19 datasets provided by the pharmaceutical industry into a single dataset. This required understanding and harmonisation of variables as well as re-anonymisation of the individual components of the dataset. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | No |
| Impact | The datasets will be provided to the MRC Biostatistics Unit at Cambridge. They are now working on identification of predictors of remission or a remission trajectory. Draft paper to be submitted Q2 2017. Second paper on transcriptomics data to be submitted Q2 2017. Multi-omics and additional papers in preparation for publication 2017-2018. |
| Title | RA-MAP-UNIVERSE |
| Description | The GitHub repository for the RA-MAP project. ALL data and code permitting prediction of remission in early arthritis patients to be made available to the wider research community. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | TBD |
| URL | https://github.com/RA-MAP-UNIVERSE |
| Title | TranSMART RA-MAP Multiomics database. |
| Description | The Innovative Medicines Initiative eTRIKS team have provided technical support to the RA-MAP informatics team (Mike Barnes lead) to assist in the deployment of an open source datamart (TranSMART) for the RA-MAP projects. The TranSMART provides a useful repository tool for important data (patient clinical data, transcriptomics, metabolomics etc) that are acquired from the RA-MAP projects. The RA-MAP TranSMART is now operational and enabling secure data sharing between consortium members. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | The Barnes team have propagated the support provided for RA-MAP to enable the deployment of additional TranSMART datamarts for the MRC-PSORT and MRC-MATURA projects. This has created a unique, common datamarts infrastructure across three closely related MRC projects investigating immune-inflammatory disease, creating opportunities for future data integration ad integrated analysis for stratified medicine and drug discovery. [Updates from March 2016] We are sharing curated public data in the database with the MRC-MATURA, MRC-PSORT and IMI-etriks projects Knowledge sharing and troubleshooting between these projects has enabled more rapid data curation and data infrastructure development for the project. We have also provided advice and troubleshooting on TranSMART configuration to the MRC-CHART (Juvenile Idiopathic Arthritis) and MRC-Masterplan (SLE) consortia [Updates from March 2017] As a complex, highly curated dataset, the RA-Map TranSMART is serving as an exemplar for development of TranSMART for the the MRC-MATURA, MRC-PSORT and MRC-MASTERPLANS projects. The project is also being used as a successful exemplar for multiple MRC stratified medicine applications. |
| Description | ARUK Centre of Excellence in rheumatoid arthritis pathogenesis |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | WE have written a successful funding application to Arthritis Research UK for a Centre of Excellence in RA pathogenesis, value £2.5m over five years |
| Collaborator Contribution | Each centre will provide a unique scientific contribution to the Centre |
| Impact | Research grant, valu £2.5m spread across the three centres. Renewed 2019 with addition of KIR, Oxford University |
| Start Year | 2013 |
| Description | ARUK Centre of Excellence in rheumatoid arthritis pathogenesis |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | WE have written a successful funding application to Arthritis Research UK for a Centre of Excellence in RA pathogenesis, value £2.5m over five years |
| Collaborator Contribution | Each centre will provide a unique scientific contribution to the Centre |
| Impact | Research grant, valu £2.5m spread across the three centres. Renewed 2019 with addition of KIR, Oxford University |
| Start Year | 2013 |
| Description | ARUK Centre of Excellence in rheumatoid arthritis pathogenesis |
| Organisation | University of Oxford |
| Department | Kennedy Institute of Rheumatology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | WE have written a successful funding application to Arthritis Research UK for a Centre of Excellence in RA pathogenesis, value £2.5m over five years |
| Collaborator Contribution | Each centre will provide a unique scientific contribution to the Centre |
| Impact | Research grant, valu £2.5m spread across the three centres. Renewed 2019 with addition of KIR, Oxford University |
| Start Year | 2013 |
| Description | ARUK-NIHR Newcastle Experimental Arthritis Treatment Centre 2016 |
| Organisation | Versus Arthritis |
| PI Contribution | Clinical, imaging, statistical and bioinformatics support. |
| Collaborator Contribution | Infrastructure support including laboratory technical support, research nurses, project management, biostatistical and database management support. This has been crucial in tendering for other awards and trials. |
| Impact | See Publications |
| Start Year | 2012 |
| Description | ARUK/NIHR Musculoskeletal Experimental Medicine Conference, Nottingham, 2018 |
| Organisation | NIHR CRN Staff and Facilities Throughout the UK |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Contributor to discussions on the UK experimental and translational medicine landscape for rheumatology. Useful networking platform whose major function was to identify potential bottlenecks across infrastructure, regulation and PPI. |
| Collaborator Contribution | Contributor to discussions on the UK experimental and translational medicine landscape for rheumatology. |
| Impact | Versus Arthritis are making a financial contribution to the NIHR NOCRI TRC in Inflammatory and Joint Diseases |
| Start Year | 2018 |
| Description | ARUK/NIHR Musculoskeletal Experimental Medicine Conference, Nottingham, 2018 |
| Organisation | Versus Arthritis |
| PI Contribution | Contributor to discussions on the UK experimental and translational medicine landscape for rheumatology. Useful networking platform whose major function was to identify potential bottlenecks across infrastructure, regulation and PPI. |
| Collaborator Contribution | Contributor to discussions on the UK experimental and translational medicine landscape for rheumatology. |
| Impact | Versus Arthritis are making a financial contribution to the NIHR NOCRI TRC in Inflammatory and Joint Diseases |
| Start Year | 2018 |
| Description | COST consortium |
| Organisation | University of Warwick |
| Department | Health Sciences Research Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This is a new European network on tolerogenic cell therapies. The network is funded by COST (European Cooperation in Science and Technology) and is called 'Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies' (A FACTT). Co-applicant Hilkens was one of the initiators of this network, and she is leading the tolerogenic APC workgroup. The main objective of A FACTT is to coordinate European cell-based tolerogenic therapy efforts to minimise overlap and maximise comparison of the diverse approaches through establishment of consensus monitoring parameters. More information can be found on: http://www.afactt.eu/ |
| Collaborator Contribution | Co-applicant Hilkens was one of the initiators of this network, and she is leading the tolerogenic APC workgroup. The main objective of A FACTT is to coordinate European cell-based tolerogenic therapy efforts to minimise overlap and maximise comparison of the diverse approaches through establishment of consensus monitoring parameters. |
| Impact | Several workshops have been held to date. |
| Start Year | 2013 |
| Description | CRO Chiltern Programme |
| Organisation | Chiltern International |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | n/a |
| Collaborator Contribution | In 2013 Chiltern Activate was employed to facilitate TACERA study (early RA longitudinal study, a part of RA-MAP consortium) set up, which resulted in significant improvement of recruitment process. From 1st April 2014 the Clinical Monitoring team at Chiltern has been re-engaged to support recruitment at poorly performing sites. |
| Impact | The RA-MAP consortium benefitted from this professional partnership by Chiltern's experience in facilitation of clinical study set up and recruitment processes. |
| Start Year | 2013 |
| Description | EULAR Task Force on Therapeutic Monitoring of Biologics |
| Organisation | Hospital de Madrid |
| PI Contribution | Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners. |
| Collaborator Contribution | TBD |
| Impact | TBD |
| Start Year | 2019 |
| Description | EULAR Task Force on Therapeutic Monitoring of Biologics |
| Organisation | Manchester University |
| PI Contribution | Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners. |
| Collaborator Contribution | TBD |
| Impact | TBD |
| Start Year | 2019 |
| Description | EULAR Task Force on Therapeutic Monitoring of Biologics |
| Organisation | NHS London |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners. |
| Collaborator Contribution | TBD |
| Impact | TBD |
| Start Year | 2019 |
| Description | EULAR Task Force on Therapeutic Monitoring of Biologics |
| Organisation | Oslo University Hospital |
| Country | Norway |
| Sector | Academic/University |
| PI Contribution | Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners. |
| Collaborator Contribution | TBD |
| Impact | TBD |
| Start Year | 2019 |
| Description | EULAR Task Force on Therapeutic Monitoring of Biologics |
| Organisation | Reade |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners. |
| Collaborator Contribution | TBD |
| Impact | TBD |
| Start Year | 2019 |
| Description | EULAR Task Force on Therapeutic Monitoring of Biologics |
| Organisation | Regional University Hospital of Tours |
| PI Contribution | Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners. |
| Collaborator Contribution | TBD |
| Impact | TBD |
| Start Year | 2019 |
| Description | EULAR Task Force on Therapeutic Monitoring of Biologics |
| Organisation | Sanquin |
| Country | Netherlands |
| Sector | Charity/Non Profit |
| PI Contribution | Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners. |
| Collaborator Contribution | TBD |
| Impact | TBD |
| Start Year | 2019 |
| Description | EULAR Task Force on Therapeutic Monitoring of Biologics |
| Organisation | St. George Hospital |
| PI Contribution | Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners. |
| Collaborator Contribution | TBD |
| Impact | TBD |
| Start Year | 2019 |
| Description | EULAR Task Force on Therapeutic Monitoring of Biologics |
| Organisation | University of Amsterdam |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners. |
| Collaborator Contribution | TBD |
| Impact | TBD |
| Start Year | 2019 |
| Description | GSK |
| Organisation | Addenbrooke's Hospital |
| Department | Addenbrooke's Centre for Clinical Investigation (ACCI) |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Analysis of biomarkers |
| Collaborator Contribution | Funding of clinical trial |
| Impact | nil yet |
| Start Year | 2009 |
| Description | IMI consortium RT-CURE |
| Organisation | Apitope |
| Country | Belgium |
| Sector | Private |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | Bristol-Myers Squibb |
| Country | United States |
| Sector | Private |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | Johnson & Johnson |
| Country | United States |
| Sector | Private |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | Leibniz Association |
| Department | German Rheumatism Research Centre |
| Country | Germany |
| Sector | Charity/Non Profit |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | Leiden University Medical Center |
| Department | Department of Rheumatology |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | Pfizer Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | Royal Berkshire Hospital |
| Department | Rheumatology Department |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | Sanofi |
| Country | Global |
| Sector | Private |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | UCB Pharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | University Hospital Erlangen |
| Department | Department of Rheumatology and Immunology |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | University of Bath |
| Department | Rheumatology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | University of Birmingham |
| Department | Institute of Cancer and Genomic Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | University of Glasgow |
| Department | Department of Rheumatology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMI consortium RT-CURE |
| Organisation | University of Queensland |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion. |
| Collaborator Contribution | Active contributions from all partners. |
| Impact | The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development. |
| Start Year | 2015 |
| Description | IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium |
| Organisation | King's College London |
| Department | School of Biomedical Sciences KCL |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards. |
| Collaborator Contribution | All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications. |
| Impact | EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful. |
| Start Year | 2018 |
| Description | IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium |
| Organisation | Queen Mary University of London |
| Department | School of Biological and Chemical Science QMUL |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards. |
| Collaborator Contribution | All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications. |
| Impact | EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful. |
| Start Year | 2018 |
| Description | IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium |
| Organisation | University of Cambridge |
| Department | Cambridge-Africa |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards. |
| Collaborator Contribution | All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications. |
| Impact | EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful. |
| Start Year | 2018 |
| Description | IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium |
| Organisation | University of Glasgow |
| Department | Mental Health Rights Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards. |
| Collaborator Contribution | All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications. |
| Impact | EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful. |
| Start Year | 2018 |
| Description | IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium |
| Organisation | University of Manchester |
| Department | Mancester Breast Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards. |
| Collaborator Contribution | All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications. |
| Impact | EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful. |
| Start Year | 2018 |
| Description | Joint TRC-Janssen Collaboration |
| Organisation | Johnson & Johnson |
| Department | Janssen Pharmaceuticals |
| Country | United States |
| Sector | Private |
| PI Contribution | Designed and performed a specific experimental medicine research study. |
| Collaborator Contribution | Designed and performed the study; analysed samples from the study. |
| Impact | Plans for future collaboration. |
| Start Year | 2016 |
| Description | King's Health Partners (Viapath) |
| Organisation | Viapath |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | n/a |
| Collaborator Contribution | Partnership with King's Health Partners (Viapath) to undertake assays for rheumatoid factor and anti-CCP antibodies, and high sensitivity CRP assays in serum from the first 300 patients recruited to the PREVeNT RA cohort of first degree relatives of patients with RA. |
| Impact | None yet. |
| Start Year | 2014 |
| Description | MATURA consortium |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | recruitment to the STRAP trial proteomic analyses |
| Collaborator Contribution | The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact. |
| Impact | Medicine statistics bioinformatics multiple industry partners |
| Start Year | 2014 |
| Description | MATURA consortium |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | recruitment to the STRAP trial proteomic analyses |
| Collaborator Contribution | The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact. |
| Impact | Medicine statistics bioinformatics multiple industry partners |
| Start Year | 2014 |
| Description | MATURA consortium |
| Organisation | Queen Mary University of London |
| Department | William Harvey Research Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | recruitment to the STRAP trial proteomic analyses |
| Collaborator Contribution | The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact. |
| Impact | Medicine statistics bioinformatics multiple industry partners |
| Start Year | 2014 |
| Description | MATURA consortium |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | recruitment to the STRAP trial proteomic analyses |
| Collaborator Contribution | The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact. |
| Impact | Medicine statistics bioinformatics multiple industry partners |
| Start Year | 2014 |
| Description | MATURA consortium |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | recruitment to the STRAP trial proteomic analyses |
| Collaborator Contribution | The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact. |
| Impact | Medicine statistics bioinformatics multiple industry partners |
| Start Year | 2014 |
| Description | MATURA consortium |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | recruitment to the STRAP trial proteomic analyses |
| Collaborator Contribution | The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact. |
| Impact | Medicine statistics bioinformatics multiple industry partners |
| Start Year | 2014 |
| Description | MATURA consortium |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | recruitment to the STRAP trial proteomic analyses |
| Collaborator Contribution | The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact. |
| Impact | Medicine statistics bioinformatics multiple industry partners |
| Start Year | 2014 |
| Description | MATURA consortium |
| Organisation | University of Hertfordshire |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | recruitment to the STRAP trial proteomic analyses |
| Collaborator Contribution | The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact. |
| Impact | Medicine statistics bioinformatics multiple industry partners |
| Start Year | 2014 |
| Description | MATURA consortium |
| Organisation | University of Leeds |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | recruitment to the STRAP trial proteomic analyses |
| Collaborator Contribution | The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact. |
| Impact | Medicine statistics bioinformatics multiple industry partners |
| Start Year | 2014 |
| Description | MATURA consortium |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | recruitment to the STRAP trial proteomic analyses |
| Collaborator Contribution | The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact. |
| Impact | Medicine statistics bioinformatics multiple industry partners |
| Start Year | 2014 |
| Description | MATURA consortium |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | recruitment to the STRAP trial proteomic analyses |
| Collaborator Contribution | The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact. |
| Impact | Medicine statistics bioinformatics multiple industry partners |
| Start Year | 2014 |
| Description | MATURA consortium |
| Organisation | University of Sheffield |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | recruitment to the STRAP trial proteomic analyses |
| Collaborator Contribution | The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact. |
| Impact | Medicine statistics bioinformatics multiple industry partners |
| Start Year | 2014 |
| Description | MRC ABPI RA MAP Project |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I am the UK Chief Investigator on the PREVeNT RA work stream in this MRC ABPI Award |
| Collaborator Contribution | There are 6 core centres involved in this collaboration and in Manchester we lead on several of the Epidemiology Projects |
| Impact | Studies are underway and early papers to follow |
| Start Year | 2011 |
| Description | MRC ABPI RA MAP Project |
| Organisation | Newcastle University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I am the UK Chief Investigator on the PREVeNT RA work stream in this MRC ABPI Award |
| Collaborator Contribution | There are 6 core centres involved in this collaboration and in Manchester we lead on several of the Epidemiology Projects |
| Impact | Studies are underway and early papers to follow |
| Start Year | 2011 |
| Description | Partnership between University of Birmingham and Protagen |
| Organisation | Protagen AG |
| Country | Germany |
| Sector | Private |
| PI Contribution | Partnership between UoB and Protagen to look at autoantibody profiles in arthritis associated with anti-PD1 therapy. This arose in part through contacts made at RA-MAP. Transfer of samples governed by MTA. |
| Collaborator Contribution | Partnership between UoB and Protagen to look at autoantibody profiles in arthritis associated with anti-PD1 therapy. This arose in part through contacts made at RA-MAP. Transfer of samples governed by MTA. |
| Impact | None yet (autoantibody profiling in arthritis patients associated with anti-PD1 therapy) |
| Start Year | 2016 |
| Description | Protagen joins as a new RA-MAP partner |
| Organisation | Protagen AG |
| Country | Germany |
| Sector | Private |
| PI Contribution | Serum samples from early RA cohort (TACERA study, n=275) together with healthy controls (from Vaccine Study, n=50) will be provided to Protagen for autoantibody profiling by Protagen's SeroTag® platform. |
| Collaborator Contribution | Protagen has examined autoantibodies to over 7,000 human proteins in the serum samples provided by the RA-MAP consortium. Protagen AG provided the technological platform, ran the analytical lab work, the statistical analysis and covered its own operational costs. |
| Impact | None yet. |
| Start Year | 2015 |
| Description | RA-MAP Consortium |
| Organisation | Abbott |
| Department | Abbott UK |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | Amgen Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | Bristol-Myers Squibb |
| Country | United States |
| Sector | Private |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | European Translational Information and Knowledge Management Services (eTRIKS) |
| Country | European Union (EU) |
| Sector | Charity/Non Profit |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | F. Hoffmann-La Roche AG |
| Country | Global |
| Sector | Private |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | Johnson & Johnson |
| Department | Janssen Pharmaceuticals |
| Country | United States |
| Sector | Private |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | MedImmune |
| Country | United States |
| Sector | Private |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | Pfizer Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | Queen Mary University of London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | UCB Pharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | University of Cambridge |
| Department | MRC Biostatistics Unit |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | University of Leeds |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | RA-MAP Consortium |
| Organisation | University of Oxford |
| Department | Kennedy Institute of Rheumatology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data |
| Collaborator Contribution | 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year. |
| Impact | N/A Too early in project to report outputs |
| Start Year | 2012 |
| Description | SOMAlogic (CRO) |
| Organisation | SomaLogic |
| Country | United States |
| Sector | Private |
| PI Contribution | Plasma samples from RA-MAP TACERA study and Vaccine study were provided for SOMAscan proteomics analysis, The resulting data have been extensively analysed by the industry members of the RA-MAP consortium. The cost of the analysis has been covered by crowd sourcing amongst the RA-MAP industry partners (£90K). |
| Collaborator Contribution | Provision of SOMAscan proteomics analysis of TACERA baseline and 6 month plasma samples, and healthy control samples from the vaccine study. |
| Impact | RA disease stratification of TACERA patients. |
| Start Year | 2016 |
| Description | SimOmics Ltd |
| Organisation | Simomics Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Provision of RA-MAP omics dataset for systems immunology collaborative project |
| Collaborator Contribution | SimOmics has been working closely with the team of systems immunologists in the RA-MAP consortium since Q1 2016. They contribute with systems analysis of RA-MAP RA omics database and metabolic flux analysis. |
| Impact | None yet |
| Start Year | 2016 |
| Description | Tepnel Pharma Services |
| Organisation | Tepnel Pharma Services |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Providing biological materials arising from TACERA clinical study cohort for RNA processing |
| Collaborator Contribution | RNA processing and miicroarray services for samples deried from TACERA clinical study |
| Impact | Tepnel has taken up the role of RNA processing and RNA microarray which feeds directly into Transcriptomics package of RA-MAP. |
| Start Year | 2015 |
| Description | WTCHG for NGS |
| Organisation | University of Oxford |
| Department | Oxford Genomics Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | RA-MAP has provided RNA samples from TACERA clinical study cohort. |
| Collaborator Contribution | Oxford Genomics has provided next generation sequencing of TACERA study RNA materials. |
| Impact | Oxford Genomics has provided expertise in generating NGS data for RA-MAP consortium. |
| Start Year | 2015 |
| Description | 'Behind the scenes' - open evening event at the Manchester Royal Infirmary rheumatology department |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | "Behind the scenes" - open evening event was held at the Manchester Royal Infirmary rheumatology department, May 2015. Patients and carers were invited to meet staff and discuss research options - talks, examples of how research is conducted, opportunity to speak to research staff |
| Year(s) Of Engagement Activity | 2015 |
| Description | 'Platform for Investigation' Event at Manchester Muserum of Science and Industry |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Manchester researchers were involved in awareness-raising activities at the Manchester Museum of Science and Industry held in April 2015. One day event with 800+ visitors, mainly families with children. |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.cmft.nhs.uk/media-centre/latest-news/explore-joints-and-genes-at-the-museum-of-science-an... |
| Description | 9th International Symposium on Uveitis Dublin 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Lecture on Biologics in Rheumatology |
| Year(s) Of Engagement Activity | 2016 |
| Description | ACR 2016 Abstract Selection Panel |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Co-chair of RA-aetiology and RA-pathogenesis categories. Reviewed 15 abstracts, selected those for presentation and ordered the session. |
| Year(s) Of Engagement Activity | 2016 |
| Description | ACR 2016 Washington |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Keynote address on 'Biologic Agents' |
| Year(s) Of Engagement Activity | 2016 |
| Description | ARUK Arthritis Matters 2014 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | There was useful discussion after my presentation about the reach of charitable funding Patients volunteered to join TRAFIC steering group |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.musculoskeletalresearch.com/2014/07/arthritis-matters-2014.html |
| Description | ARUK Strategy Meeting Newcastle 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Strategy discussion with Liam O'Toole and Steve Simpson |
| Year(s) Of Engagement Activity | 2016 |
| Description | ARUK T-reg Workshop, London, 2018 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Supporters |
| Results and Impact | A workshop that involved several charities and international experts. The goal to promote collaborative research and funding around the role of Tregs in autoimmune diseases. |
| Year(s) Of Engagement Activity | 2018 |
| Description | ARUK/CRUK Joint Planning Meeting |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Joint planning meeting for symposium embracing common interests eg. checkpoint inhibitors. |
| Year(s) Of Engagement Activity | 2016 |
| Description | ASPIRE 2016 Research Awards |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Pfizer rheumatology research awards. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.aspireresearch.org/Rheumatology/index.html |
| Description | Adherence Workshop - Manchester 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Organized by my ARUK CSG - workshop on treatment adherence. |
| Year(s) Of Engagement Activity | 2016 |
| Description | American College of Rheumatology (November 2015, California) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | PREVeNT RA Serum Biomarkers abstract was an abstract for a talk given by Prof Bruce at the ACR (American College of Rheumatology) November 2015 |
| Year(s) Of Engagement Activity | 2015 |
| Description | An Embrassment of Riches |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | 100 individuals attended a session at BSR which I had organised, highlighting the importance of engaging patients in research This activity should improve recruitment to clinical trials, particularly from non-academic centres |
| Year(s) Of Engagement Activity | 2013 |
| Description | Antigen-Specific Immune Tolerance Europe, London, 2018 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Presented on RA-MAP and the TRC as examples of acadaemia-industry collaboration. Useful industry contacts on peptide therapeutics, CAR T-cells and other biotechnologies. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.as-immunetolerance-eu.com/ |
| Description | BSR 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Best practice in rheumatology research. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.rheumatology.org.uk/ |
| Description | BSR 2016 Abstracts |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Reviewed 26 BSR Abstracts |
| Year(s) Of Engagement Activity | 2016 |
| Description | BSR 2016 Glasgow Signalling Pathways 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Chaired the Pfizer session on Signalling Pathways |
| Year(s) Of Engagement Activity | 2016 |
| Description | BSR Manipulating The Immune System - Birmingham |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | This was a lecture to rheumatologists in training on novel immunologically based therapies, at the annual BSR AGM. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.eiseverywhere.com/ehome/rheumatology2017/423982/ |
| Description | BT-CURE Workshop - Stockholm 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | AuToDeCRA Lecture and RT-CURE IMI proposal |
| Year(s) Of Engagement Activity | 2016 |
| Description | BT-CURE workshop May 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was a workshop of an existing EU-FP& consortium, which is now developing an IMI application for tolerogenic therapies in RA. I was invited to participate as a member of the proposed IMI academic/industry consortium |
| Year(s) Of Engagement Activity | 2016 |
| Description | Biomedical Research Unit Open Day (Manchester) - Disease Prevention |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | The Biomedical Research Unit (Musculoskeletal) in Manchester held its annual open day in May 2014, with this year's theme being on disease prevention. The open day provided staff from the regional institutions, hospitals and members of public to learn more about the research being carried out into disease prevention. This included a presentation given by Professor Ian Bruce on the PREVeNT RA study, introducing the study focussed on prevention of rheumatoid arthritis. Increased public awareness of currently on-going studies aimed at disease prevention, in particular rheumatoid arthritis. |
| Year(s) Of Engagement Activity | 2014 |
| Description | CLUSTER Consortium - London, 2018 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | Strategic plans for MRC-funded stratified medicine programme in JIA and associated Uveitis. JDI chairs the external SAB. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://juvenilearthritisnews.com/2018/04/02/cluster-consortium-aims-improve-jia-uveitis-patients-li... |
| Description | Cafe Scientifique (PREVeNT RA), Cockermouth, Cumbria |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | Professor Ian Bruce (PI for the PREVeNT RA study) gave a presentation of arthritis, based on his research. It provoked significant discussion about how lifestyle may influence arthritis development. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Cafe Scientifique (PREVeNT RA), Pendle, Lancashire |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Professor Ian Bruce (PI for the PREVeNT RA study) gave a presentation of arthritis, based on his research. It provoked significant discussion about how lifestyle may influence arthritis development. Professor Bruce has been invited to give a further talk and the group sent a recording of his talk to other similar groups in England to raise awareness. |
| Year(s) Of Engagement Activity | 2014 |
| Description | Central & Eastern European Immunology Forum Bucharest 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | New Treatments for Immune Mediated Inflammatory Diseases |
| Year(s) Of Engagement Activity | 2016 |
| Description | Clinical Decision Making - Statistics and Health Economics |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Latent variable methods for clinical decision tools. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Conservative Muslim Forum (London) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Professor Ian Bruce presented a talk to explore the question "Precision Medicine : An Achievable Goal?" He discussed how precisely can diseases be treated in a way that is specific to the individual patient. He gave an in depth analysis of research in Rheumatology and the fact that there are 8 million people affected by the disease. Despite the complexity of the subject, Professor Bruce managed to make it accessible to the layman. Professor Bruce alos talked about how research in the UK is fundedm and gave a breakdown of the various research being done by Medical Research Council and the National Institute of Health Research. Whilst the NHS's total budget is over £100 billion, the share devoted to research is under 3%. For most people, the most fascinating part of the evening was listening to Professor Bruce on the general theme of medication. He he talked about medicine being "partly art, partly science." Most drugs prescribing is on a trial and error / best guess basis, using the likely benefit to the average person. He talked about "personalised medicine" which would target the medicine to the individual patient, and "stratified medicine" which groups patients into categories to assess which medicine to use, being intermediate between using data for the average person and data for the specific individual. |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.conservativemuslimforum.com/news~events/news-&-past-events/health-event-precision-medicin... |
| Description | DMC MATCH Macrophage Study Newcastle 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Study of macrophage therapy in liver cirrhosis. |
| Year(s) Of Engagement Activity | 2016 |
| Description | DRFZ Scientific Advisory Board Meeting Berlin 2016 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | DRFZ is Germany's premier Rheumatology Institute - Radbruch |
| Year(s) Of Engagement Activity | 2016 |
| Description | Drug Discovery Catapult - Alderley Park |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Third sector organisations |
| Results and Impact | Discussions with the Medicines Discovery Catapult around access by SMEs to RA-MAP biobanked samples. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://md.catapult.org.uk/ |
| Description | EMEUNET Meeting Lisbon 2016 Immune Tolerance - Where Next? |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Immune Tolerance: RA - Where Next? |
| Year(s) Of Engagement Activity | 2016 |
| Description | EMINENT GSK |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | To discuss a new funding stream from GSK and MRC for collaborative, experimental medicine research |
| Year(s) Of Engagement Activity | 2015 |
| Description | EULAR 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prospective collaboration with Pfizer |
| Year(s) Of Engagement Activity | 2015 |
| Description | EULAR 2016 London |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Chaired the satellite symposium on Biosimilars - Kweim, Dorner - presentation on Refractory RA |
| Year(s) Of Engagement Activity | 2016 |
| Description | EULAR 2019 Organizing Committee |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Preparing for EULAR 2019 (Madrid). JDI is Abstracts Chair, a majpr role in the organising committee.. |
| Year(s) Of Engagement Activity | 2018,2019 |
| URL | https://www.congress.eular.org |
| Description | EULAR Research Centre, London, 2019 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Strategic discussions around a prospective, collaborative, virtual research centre for European Rheumatic and Musculoskeletal Disorders groups. |
| Year(s) Of Engagement Activity | 2019 |
| Description | EULAR Scientific Programme Committee |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Planning meeting for EULAR 2019 in Madrid. As Abstract Chair I play a major role in this meeting. |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://congress.eular.org/index.cfm |
| Description | EULAR Therapeutic Drug Monitoring Study Group, Amsterdam, 2018 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Chaired this EULAR Study Group reviewing therapeutic drug monitoring. Decision taken to apply for EULAR Task Force status in 2019. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.eular.org/clinical_affairs_study_groups.cfm |
| Description | Efficient Medical Technology Development 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Facilitated workshop mapping roadblocks to the development pathway for new technologies. |
| Year(s) Of Engagement Activity | 2017 |
| Description | European Workshop for Rheumatology Research, Lyon, 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Annual research workshop, provides the opportunity for postgrad students and ECRs to present their work to an international audience. One of our students had an oral presentation and another presented a poster. |
| Year(s) Of Engagement Activity | 2019 |
| URL | http://www.ewrr.org/ |
| Description | GSK Industry Engagement Visit Newcastle 2016 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Explored shared interests - potential for interaction - biopsy procedures |
| Year(s) Of Engagement Activity | 2016 |
| Description | Genesis Conference (London) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dr Mike Barnes presented a talk entitled: Technologies empowering Omics in the sessioin "Empowering Technologies" |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.cambridgeahead.co.uk/2015/12/genesis-2015-london-10th-december/ |
| Description | Genomics Research in the NE Quadrant - York |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Participation in meeting on the future of genomics research in the NE Quadrant, as a component of NHS England's reorganisation of clinical genetics services. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Great North Experimental Arthritis Treatment Centre website |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | The activity is ongoing |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.greatneatcentre.com/ |
| Description | IMID-BIO Cambridge, 2018 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | Annual scientific and strategic planning meeting for IMID-BIO UK. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.arthritisresearchuk.org/research/news-for-researchers/2017/december/our-role-in-the-worl... |
| Description | IMID-BIO Science Day - Glasgow |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Scientific meeting of the IMID-BIO project, which brings together several stratified medicine consortia. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Immune mediated Inflammatory Diseases Workshop: Wellcome Trust |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | This 2 day workshop brought together a wide spectrum of experts across immune mediated diseases to discuss challenges and future opportunities to learn more about immune mediated conditions. Several potential collaborations were discussed |
| Year(s) Of Engagement Activity | 2017 |
| Description | Immunogenicity Research Forum 2015 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prospective collaborations |
| Year(s) Of Engagement Activity | 2015 |
| Description | International Forum for RA |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The International Forum for RA is a meeting focussed on cutting edge research in rheumatoid arthritis, with an emphasis on influencing future management strategies. I gave a presentation around 'smart trial designs'. This led to a new collaboration with Dana Orange (Rockefeller). |
| Year(s) Of Engagement Activity | 2017 |
| Description | International Psoriasis Council Symposium, Munich September 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | I spoke on P4 medicine in rheumatology and how such an approach can better address patient stratification |
| Year(s) Of Engagement Activity | 2016 |
| Description | Inventory of Trials Study Workshop on Predictors of Remission Study |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Workshop for the Predictors of Remission study was organised in Manchester by Prof Jane Worthington, Prof Deborah Symmons, Prof Ian Bruce and Ms Fiona Stirling. The workshop provided an opportunity to feed back information and analyses of the pooled clinical datasets from the 7 consortium member organisations. The meeting was successful, supported by approximately 20 participants contributing from these organisations (mixture of academic and industry partners). The findings of the study are planned to be incorporated into a manuscript under preparation by Prof Deborah Symmons. This workshop also promoted further data to be produced in order to strengthen the powering of the results. In addition, Brian Tom (study statistician for the RA-MAP consortium) was invited to speak at PSI (Statisticians in the Pharmaceutical Industry) conference in May 2015. |
| Year(s) Of Engagement Activity | 2014 |
| Description | JDRF Workshop - Common Mechanisms of Autoimmune Conditions |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prospective collaborations |
| Year(s) Of Engagement Activity | 2015 |
| Description | Janssen Disease Area Stronghold Scientific Symposium Newark 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Featuring imaging presentations. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Launch of the Medicines Discovery Catapult (January 2017, Alderley Park) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | The Catapult is an important partner for our BRC and this launch event introduced us to new collaborators and potential funding streams |
| Year(s) Of Engagement Activity | 2018 |
| Description | Lecture on "Stratified approaches to the treatment of rheumatoid arthritis" (Newcastle University MSc in Genomic Medicine) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | Newcastle PI John Isaacs gave a lecture on stratified medicine in RA to the Genomics Medicine MSc at Newcastle University. This was provided to medical students who all work full time in the NHS. |
| Year(s) Of Engagement Activity | 2016 |
| Description | MATURA Scientific Symposium - Manchester |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Scientific meeting bringing together the findings of the MATURA trial. Newcastle presented data on our proteomics analysis. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.matura.whri.qmul.ac.uk/what_is_matura.php |
| Description | MATURA Workshop 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentations by ES and CMB |
| Year(s) Of Engagement Activity | 2017 |
| Description | MRC DPFS Meeting - London |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The DPFS scheme is a key part of the MRC's Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including "repurposing" of existing therapies. Remit The scheme supports academically led projects whose goals are to improve prevention, diagnosis, prognosis, or treatment of significant health needs, or that focus on developing research tools that increase the efficiency of developing interventions. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.mrc.ac.uk/funding/browse/biomedical-catalyst-dpfs/biomedical-catalyst-developmental-path... |
| Description | MRC DPFS Panel Meeting - London 2016 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Reviewed seven outline applications and two full applications for MRC Development Pathway Funding Scheme. |
| Year(s) Of Engagement Activity | 2016 |
| Description | MRC Newcastle University Visit |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Review and round table discussions of Newcastle University research outputs and statistics. |
| Year(s) Of Engagement Activity | 2018 |
| Description | MRC Platforms Workshop |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dr Michael Barnes presented a talk entitled "Platforms for Data integration" |
| Year(s) Of Engagement Activity | 2015 |
| Description | MRC RA-MAP CMB and PSG Meetings London 2016 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Strategic planning around future research directed at predictors of remission in RA. |
| Year(s) Of Engagement Activity | 2016 |
| Description | MRC Research Strategy Visit 2016 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Reviewed medical research at Newcastle highlighting achievements in experimental medicine and translational research and identifying improvement opportunities. |
| Year(s) Of Engagement Activity | 2016 |
| Description | MRC Stratified Medicine Consortia in Immune-Inflammatory Diseases Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | This workshop explored common characteristics across a number of key consortia and has helped to better understand common challenges in the mechanisms of these conditions as well as common methodological challenges |
| Year(s) Of Engagement Activity | 2016 |
| Description | MRC Stratified Medicine Initiative - Strategy Workshop 2013 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | MRC Stratified Medicine Strategy Workshop 4th July 2013 London Science of Strat Med Consortia - Assisted the broader community in better understanding the opportunities and challenges posed by taking a stratified medicine approach |
| Year(s) Of Engagement Activity | 2013 |
| Description | MRC Stratified Medicine, London, 2018 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | Review of progress for the MRC Stratified Medicine Consortia and Pathology Nodes. |
| Year(s) Of Engagement Activity | 2018 |
| Description | MRC TRG Meeting - London |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The MRC Translational Research Group (TRG) is responsible for ensuring strong continued support for translational research across the MRC. It supports translational research across MRC funding Boards and Panels, through partnerships with other funders and major Higher Education Institutions and through dedicated funding schemes. Areas of particular focus for TRG include: The Biomedical Catalyst, an integrated translational funding programme jointly operated with Innovate UK (formerly the Technology Strategy Board). The Confidence in Concept scheme, supporting academically led feasibility research at the institutional level. The Developmental Pathway Funding Scheme, part of the Biomedical Catalyst, supporting translation of fundamental discoveries toward benefits to human health. The Methodology Research Programme, in partnership with the National Institute for Health Research (NIHR). Coordination with the MRC-NIHR Efficacy and Mechanism Evaluation Programme (EME) programme and other NIHR funding schemes to ensure suitable projects progress to late-stage trials. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.mrc.ac.uk/about/our-structure/strategy-board-overview-groups/translational-research-grou... |
| Description | MRC Technology Strategy Board Stratified Medicine Showcase |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | MRC Technology Strategy Board Stratified Medicine Showcase 30th Oct 2013 London Delivering the Impact To be reported |
| Year(s) Of Engagement Activity | 2013 |
| Description | MRC Translational Research Group 2016 Strategy Meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Developing translational research strategy for the UK |
| Year(s) Of Engagement Activity | 2016 |
| Description | MRC/ABPI RA-MAP Final Meeting - London |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Sharing the research results of the RA-MAP project. |
| Year(s) Of Engagement Activity | 2017 |
| Description | MRCstratified medicine workshop April 2014 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Audience of approximately 20 PIs plus MRC staff - a view from the expert panel Enhanced recognition for Newcastle as a centre for translational medicine |
| Year(s) Of Engagement Activity | 2014 |
| Description | MSc Genomics Newcastle 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | Stratified Medicine in RA |
| Year(s) Of Engagement Activity | 2016 |
| Description | Methodology for Stratified Medicine |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prospective collaborations |
| Year(s) Of Engagement Activity | 2015 |
| Description | NE Inflammation Forum - Newcastle 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Pfizer chair - Coady, Goff, Sheikh, Taylor, Thompson. |
| Year(s) Of Engagement Activity | 2016 |
| Description | NHSA Meeting ( September 2017, Newcastle) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | NHSA meeting to plan collaborative work across the Northern BRCs |
| Year(s) Of Engagement Activity | 2017 |
| Description | NICE Diagnostic Advisory Committe, Manchester, 2019 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Development of draft recommendations on Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis. These will be published for public consultation before formal recommendations are published. |
| Year(s) Of Engagement Activity | 2019 |
| Description | NIHR BRC Impact Showcase, Newcastle, 2018 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Showcase event attended by senior figures from the Department of Health and major charities including Versus Arthritis. The CEOs of the Trust and University attended. Musculoskeletal presentations included patient presentations and videos. Ken Baker was awarded a prize for best oral presentation. Sir John Burn and Dame Jackie Daniel presented their vision for Newcastle. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.newcastlebrc.nihr.ac.uk/events/nihr-newcastle-biomedical-research-centre-impact-showcase... |
| Description | NIHR TRP Committee Meeting 2016 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | TRP strategic meeting. |
| Year(s) Of Engagement Activity | 2016 |
| Description | NIHR TRP Pipeline Meeting - London 2016 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Discussed pipeline and promotion of early stage trials - limitations of PIC sites - BRC roles |
| Year(s) Of Engagement Activity | 2016 |
| Description | NOVARTIS Biomedical Research Foundation (June 2017, Mayfair) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | A meeting between NIHR and Novartis to discuss potential engagement of Novartis in the UK |
| Year(s) Of Engagement Activity | 2017 |
| Description | NRAS magazine article |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Type Of Presentation | Paper Presentation |
| Geographic Reach | National |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Article on the importance of adherence to therapy for NRAS magazine This magazine has a wide circulation amongst patients with RA and is also available on-line |
| Year(s) Of Engagement Activity | 2014 |
| Description | Non-Pharmacological Interventions Workshop ARUK AIA CSG |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prospective collaborations |
| Year(s) Of Engagement Activity | 2015 |
| Description | Open Innovation in the NHS workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | On the 2nd April 2014 the Academy of Medical Sciences hosted a workshop in partnership with the Centre for the Advancement of Sustainable Medical Innovation (CASMI) to bring together members of academia, industry, the NHS, funding bodies and IP experts. The discussion focused on the key issues and opportunities surrounding collaboration with the NHS, focusing particularly on 'open innovation' models of partnership. Professor Andrew Cope (PI of RA-MAP study) contributed by presenting the MRC/ABPI-funded RA-MAP consortium as an exemplar of open innovation in the NHS and model of academia-NHS-industry collaboration. Delegates enjoyed four case presentations that highlighted the advantages of open collaboration models and also some of the barriers and frustration involved with these partnerships. Following a candid and constructive period of discussion, delegates highlighted four areas that they considered to be the most significant barriers to open innovation. These were: lack of metrics, poor incentivisation and reward for innovation, cultural conflicts between sectors and poor use of existing structures. Delegates then worked in groups to consider novel solutions to overcoming these barriers and facilitate open innovation partnerships with the NHS. |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.acmedsci.ac.uk/policy/policy-projects/open-innovation-in-the-nhs/ |
| Description | Personalized Medicine - Brazil 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Lecture tour presenting four talks on Personalized Medicine at three research centres in Brazil. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Pfizer 2016 Berlin Meeting to develop educational materials around Tofactinib treatment. |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Meeting to develop educational materials to support Tofactinib treatment sponsored by Pfizer. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Pfizer EARTH Ad Board - Paris 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Co-chaired the Ad Board |
| Year(s) Of Engagement Activity | 2016 |
| Description | Pfizer JAK Inhibition Symposium 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talks and informal discussions on RA pathophysiology and potential novel treatments. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Portuguese Congress of Rheumatology 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Networking and strategic planning with international collaborators. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Portuguese Society of Rheumatology - Algarve 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Keynote Lecture - New Treatments for IMID - invited paper to Annals Review |
| Year(s) Of Engagement Activity | 2016 |
| Description | Precision Medicine UK |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | NOCRI joined UK leaders in the research, development and commercialisation of precision medicine for a one-day event this week designed to encourage new partnerships and highlight new opportunities in the field. The Precision Medicine UK: Collaboration Nation event at De Vere Holborn Bars, London, on 9 December was organised on behalf of the Stratified Medicine Innovation Platform by Innovate UK,, National Institute for Health Research, Cancer Research UK,Medical Research Council, Invest Northern Ireland, Health and Care Research Wales and the Knowledge Transfer Network, with the NIHR Office for Clinical Research Infrastructure (NOCRI) coordinating the NIHR's involvement. The day formed part of a programme to make the UK a world leader in precision medicine and provided real-world examples of the discovery and development of precision medicine solutions, through talks, panel discussions, workshops and exhibitions with the opportunity to arrange one-to-one partnering meetings. Precision medicine is an emerging approach to the treatment and diagnosis of disease that takes into account variations in a patient's genes, environment and lifestyle. It aims to better target treatments to an individual's circumstances to improve outcomes for patients. Representatives from across the NIHR were involved in the day and presented on a range of projects and funding programmes. Professor Bryan Williams of NIHR UCLH Biomedical Research Centre joined the first panel of the day which highlighted UK investments in the invention and evaluation phase of research. Professor Williams' highlighted key NIHR's investments in this space and provided examples of exciting precision medicine projects from UCLH BRC. In addition, a number of NIHR precision medicine projects were presented during the disease area specific showcase sessions. This included Professor Costantino Pitzalis who presented the THERAPIST study on behalf of the NIHR Translational Research Partnership, Professor Simon Mead's who presented a project at NIHR Queen's Square Biomedical Research Unit on the "dementia chip" and Professor Tariq Sadiq's who presented on Capacity Building and Delivery of Precision Medicine in Sexual Health, through NIHR Funding. Mark Samuels, Managing Director of NOCRI, also chaired a discussion panel themed 'Enabling Collaboration', which highlighted the value of collaborative working between companies, academics, charities and patients. The event saw the launch by the chief executive of Innovate UK, Dr Ruth McKernan, of a new map of the precision medicine landscape. A whole range of organisations, including charities, health bodies and devolved administrations are coordinating their work under the umbrella of Innovate UK's Stratified Medicine Innovation Platform, with NOCRI representing the NIHR. |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.uk-pgx-stratmed.co.uk/index.php/event-calendar/icalrepeat.detail/2015/12/09/213/73/- |
| Description | Presentation to Industrial partners at American Congress of Rheumatology meeting in San Diego |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Approximately 40 attendees from 18 different companies. Introduced the NHIR Translational Research Partnership to them. (Title: the NIHR Translational Research Partnership). Several contacts subsequent to the meeting with potential collaborative research ensuing. |
| Year(s) Of Engagement Activity | 2013 |
| Description | R&D conference. Health Research - partnerships for success |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | This was a conference at BMA House organised by ABPI, BIA and NOCRI - to explain largely to an industrial audience, how the collaborative landscape (Industry/academia) was evolving. Other speakers included Lord Howe and Sir John Savill. There were approximately 250 attendees. New contacts from potential industrial collaborative partners |
| Year(s) Of Engagement Activity | 2012 |
| Description | RA-MAP Biostatistics overview (presentation at MATURA meeting) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | RA-MAP Biostatistics Overview was presented by Brian Tom (RA-MAP statistician PI) at MATURA Scientific Meeting, where the statistical approaches used in RA-MAP were outlined, which may be relevant to the MRC Stratified Medicine Initiative MATURA consortium |
| Year(s) Of Engagement Activity | 2017 |
| Description | RA-MAP Presentation at PSI Immunology Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Brian Tom, the leading PI statistician of RA-MAP, provided RA-MAP project overview and statistical approaches taken in a presentation given at PSI (Promoting Statistical Insight) Immunology meeting to industry statisticians. |
| Year(s) Of Engagement Activity | 2016 |
| Description | RA-MAP data infrastructure and analysis strategy presented at Wellcome Trust Immune Modulated Inflammatory Disease Workshop (Feb 2017) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | RA-Map data infrastructure and analysis strategy was presented |
| Year(s) Of Engagement Activity | 2017 |
| Description | RA-MAP data infrastructure was presented as an exemlar at the MRC Stratified Medicine Applicats Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | RA-Map data infrastructure was presented as an exemplar at the MRC Stratified Medicine applicants workshop |
| Year(s) Of Engagement Activity | 2017 |
| Description | RA-MAP project presentation as a Startified Medicine exemplar at the MRC-eMedLab Stratified Medicine Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The RA-Map project was presented as a Stratified Medicine exemplar at the MRC-eMedLab Stratified Medicine workshop |
| Year(s) Of Engagement Activity | 2016 |
| Description | RA-MAP website |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | The RA-MAP website is currently hosted by Newcastle University but serves the needs of Consortium members - the numerous industry and academic partners making up the RA-MAP consortium. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://research.ncl.ac.uk/ra-map/ |
| Description | RA/MAP Closure meeting (June 2017, London) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Closure of the RA MAP consortium with presentations on relevant outputs and future plans |
| Year(s) Of Engagement Activity | 2017 |
| Description | RACE Scientific Advisory Board Meeting 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentations on TRAFIC and BIO-FLARE as worked examples of our experimental medicine approach. |
| Year(s) Of Engagement Activity | 2016 |
| Description | RACE Second International Scientific Advisory Board Meeting, Glasgow, 2018 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | Scientific presentations and patient-focused discussions. Excellent feedback from the panel, which has influenced.renewal plans. |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.race-gbn.org/communityengagement/ |
| Description | RACE launch |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Interesting discussions, including with an Olympian None yet |
| Year(s) Of Engagement Activity | 2014 |
| Description | RT-CURE Annual Meeting, Beerse, 2018 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | Annual meeting of the RT-CURE consortium. Excellent meeting with welcome patient partner participation. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Remission Accomplished - Houses of Parliament |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | There was an active discussion around the therapy of inflammatory arthritis and its future direction. None yet |
| Year(s) Of Engagement Activity | 2014 |
| Description | Research Engagement Poster Campaign 2015 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Poster campaign describing research in lay terms for public and patients audience. To promote engagement in research in the NE. Public and patients expressed interest in participating in research. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Rheumatoid Arthritis Strategic Review, Newcastle, 2015 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Strategic realignment of research activities |
| Year(s) Of Engagement Activity | 2015 |
| Description | Rheumatoid Arthritis: What's New? Karolinska, Sweden 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Novel and targeted RA treatments. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Rheumatology Research Patient Partnership (R2P2) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Education and empowernig Patient Partners to participate in research design and oversight. Education and empowering Patient Partners to participate in research design and oversight. The Rheumatology Research Group in Birmingham recognise the importance of involvement of patients and members of the general public in all aspects of the research process, including initial project development and grant applications, the design and implementation of the studies as well as their dissemination. |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.birmingham.ac.uk/research/activity/mds/projects/ii/R2P2/index.aspx |
| Description | Roche Systems Pharmacology Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | A systems approach to investigating drug response variability in RA |
| Year(s) Of Engagement Activity | 2015 |
| Description | Royal College of Physicians of Edinburgh Therapeutic Drug Monitoring Conference, Edinburgh, 2018 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Workshop focussed on therapeutic drug monitoring for biologic therapies including round table discussion and establishment of a working group. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Seminar at Altnagelvin Hospital |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Prof Ian Bruce provided a seminar about pevention of RA based on PREVENT RA study. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Stockholm - RA: What's Next - 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited Lecture |
| Year(s) Of Engagement Activity | 2016 |
| Description | Stratified Medicine Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prospective collaborations |
| Year(s) Of Engagement Activity | 2015 |
| Description | TACERA Premier 2 London 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Hosted the day. Introductory Presentation. |
| Year(s) Of Engagement Activity | 2016 |
| Description | TEDx Newcastle |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | It provided an opportunity to highlight the importance of patient participation in experimental medicine and translational research studies The TEDx Newcastle website has received more than 10000 hits |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.greatneatcentre.com/2014/07/the-patient-who-changed-my-life-people.html |
| Description | Translational Research Collaboration Steering Group Meeting (February 2018) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The quarterly TRC meetings help us to develop a strategy for the TRC and industry links including new SLE and RA studies/trials |
| Year(s) Of Engagement Activity | 2018 |
| Description | UK Autoimmunity Workshop - Defining the Grand Challenges - Clinical Trials, New Therapeutics, Repurposing |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | JDRF MRC ARUK WT |
| Year(s) Of Engagement Activity | 2016 |
| Description | Visit to China to key universities (January 2018, China) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Our university visited 4 Chinese universities. We planned and discussed future collaborations including student exchanges, collaborative grants and future visits |
| Year(s) Of Engagement Activity | 2018 |